EP0362526A2 — The Alpha-subunit of the LFA-1 leukocyte adhesion receptor
Assigned to Dana Farber Cancer Institute Inc · Expires 1990-04-11 · 36y expired
What this patent protects
The present invention relates to LFA-1 alpha-subunit which is involved in the process through which cell recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, the functional de…
USPTO Abstract
The present invention relates to LFA-1 alpha-subunit which is involved in the process through which cell recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, the functional derivatives of such molecules, screening assays for identifying such molecules and therapeutic and diagnostic uses for such molecules.
Drugs covered by this patent
- Xiidra (LIFITEGRAST) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.